{"id":"W3182666754","doi":"10.1158/1538-7445.am2021-ct006","title":"Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Cohort; Tolerability; Discontinuation; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Clinical trial; Adverse effect; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001370635,0.001129691,0.0009855903,0.0003127607,0.0003722441,0.0007159772,0.00074963,0.000794797,0.008137896],"category_scores_gemma":[0.0007480579,0.0002873805,0.0006655605,0.0003629292,0.0004358092,0.0005425879,0.0003781367,0.002325766,0.001676437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006516867,"about_ca_system_score_gemma":0.001445447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006666318,"about_ca_topic_score_gemma":0.002046934,"domain_scores_codex":[0.9996667,0.0001722076,0.00002185696,0.0000481753,0.00004840368,0.00004268739],"domain_scores_gemma":[0.9996012,0.00005566664,0.00008898693,0.00002855968,0.00003477123,0.0001908384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7241619,0.04480888,0.01027391,0.001957333,0.001050578,0.0005828044,0.0002073098,0.002063934,0.0980716,0.0004815929,0.01368659,0.1026536],"study_design_scores_gemma":[0.6330098,0.3272167,0.01740858,0.00009850619,0.0006280856,0.0007931823,0.00005863703,0.001292374,0.0091999,0.0001865426,0.01007172,0.0000360328],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737279,0.003492508,0.001301972,0.0005777509,0.0001541576,0.007629241,0.006429377,0.0002611194,0.006425914],"genre_scores_gemma":[0.9672284,0.002054131,0.003330914,0.001355034,0.0002499518,0.005567272,0.01260057,0.00005139242,0.00756235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008137896,"threshold_uncertainty_score":0.02722394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09035054185042334,"score_gpt":0.4364000889593772,"score_spread":0.3460495471089539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}